Fig. 6: Genes upregulated by oncogenic MEK1(K57N) serve as cancer signature genes. | Nature Communications

Fig. 6: Genes upregulated by oncogenic MEK1(K57N) serve as cancer signature genes.

From: Qualitative differences in disease-associated MEK mutants reveal molecular signatures and aberrant signaling-crosstalk in cancer

Fig. 6

a–d qRT-PCR analyses of the sigmoidal-B group of genes. The genes were classified as encoding secreted (a), transmembrane (b), or cytoplasmic/nuclear (c) proteins, or long intergenic non-coding RNAs (lncRNAs) (d). Data are mean ± SEM from three independent experiments. P-values were assessed using one-way ANOVA followed by Tukey’s multiple comparisons test. ns, not significant. e, f The expression levels of the indicated proteins in HEK293 cells expressing HA-MEK1(WT, F53S, or K57N) (e) and in H1299 cells (f) were assessed by immunoblotting with the appropriate Abs. Where indicated, the cells were pretreated with the MEK inhibitor U0126 for 24 h. g, h TransFac analysis of the promoter regions of the genes upregulated (>2-fold, p < 0.05) in K57N cells. The graphs show the number of target genes of the transcription factors (TFs) that are increased (>2-fold) in expression (g) and of the TFs that show no or weak change (0.5- to 2-fold) in expression (h) vs. control cells. Source data are provided as a Source Data file.

Back to article page